Evidence map›Paper›PMID 38605183›Full record

ArticleNature metabolism2024

Adipose tissue macrophages secrete small extracellular vesicles that mediate rosiglitazone-induced insulin sensitization.

Theresa V Rohm, Felipe Castellani Gomes Dos Reis, Roi Isaac, Cairo Murphy, Karina Cunha E Rocha, Gautam Bandyopadhyay, Hong Gao, Avraham M Libster, Rizaldy C Zapata, Yun Sok Lee and 4 more

Erratum issuedOpen access · greenAbstract read
In one paragraph

Article in Nature metabolism, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 34 papers.

0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed
11.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

34 citing papers in PubMed, 34 citations in OpenAlex.

  1. Review
  2. Mesenchymal Stromal Cell-Based Cell-Drug Conjugates for the Treatment of Acute Liver Failure.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026
    Article
  3. Article
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Review
  18. Emerging role of exosomal-microRNA in obesity.Current opinion in physiology · 2025
    Article
  19. Review
  20. Therapeutic Applications of Poly-miRNAs and miRNA Sponges.International journal of molecular sciences · 2025
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

14 authors at 2 institutions in 1 country.

Theresa V RohmDivision of Endocrinology and Metabolism, Department of Medicine, University of California San Diego, La Jolla, CA, USA. trohm@health.ucsd.edu.ORCID http://orcid.org/0000-0001-8498-1018
Felipe Castellani Gomes Dos ReisDivision of Endocrinology and Metabolism, Department of Medicine, University of California San Diego, La Jolla, CA, USA.ORCID http://orcid.org/0000-0001-8357-5261
Roi IsaacDivision of Endocrinology and Metabolism, Department of Medicine, University of California San Diego, La Jolla, CA, USA.
Cairo MurphyDivision of Endocrinology and Metabolism, Department of Medicine, University of California San Diego, La Jolla, CA, USA.
Karina Cunha E RochaDivision of Endocrinology and Metabolism, Department of Medicine, University of California San Diego, La Jolla, CA, USA.
Gautam BandyopadhyayDivision of Endocrinology and Metabolism, Department of Medicine, University of California San Diego, La Jolla, CA, USA.
Hong GaoDivision of Endocrinology and Metabolism, Department of Medicine, University of California San Diego, La Jolla, CA, USA.
Avraham M LibsterDivision of Endocrinology and Metabolism, Department of Medicine, University of California San Diego, La Jolla, CA, USA.
Rizaldy C ZapataDivision of Endocrinology and Metabolism, Department of Medicine, University of California San Diego, La Jolla, CA, USA.
Yun Sok LeeDivision of Endocrinology and Metabolism, Department of Medicine, University of California San Diego, La Jolla, CA, USA.ORCID http://orcid.org/0000-0001-7967-4734
Wei YingDivision of Endocrinology and Metabolism, Department of Medicine, University of California San Diego, La Jolla, CA, USA.ORCID http://orcid.org/0000-0002-4890-7256
Charlene MicianoCenter for Epigenomics, University of California San Diego, La Jolla, CA, USA.ORCID http://orcid.org/0000-0001-7653-8876
Allen WangCenter for Epigenomics, University of California San Diego, La Jolla, CA, USA.ORCID http://orcid.org/0000-0001-9870-7888
Jerrold M OlefskyDivision of Endocrinology and Metabolism, Department of Medicine, University of California San Diego, La Jolla, CA, USA. jolefsky@health.ucsd.edu.ORCID http://orcid.org/0000-0003-0392-1705
University of California San Diego · USUC San Diego Health System · US

Funding

The Southernearch Center for ALPD and CirrhosisP50AA011999 · NIAAA · UNIVERSITY OF SOUTHERN CALIFORNIA · PI HIDEKAZU TSUKAMOTO · 1999 to 2026
$45.8M
Transgenic & Knock-out MouseP30DK063491 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI MILES Frome WILKINSON · 2003 to 2026
$40.4M
San Diego Digestive Diseases Research CenterP30DK120515 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Bernd G. Schnabl · 2019 to 2026
$10.8M
Transcriptional co-regulators and macrophage gene expressionR01DK091183 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI GLASS, CHRISTOPHER K · 2011 to 2025
$9.9M
Inactivation of Hepatic Stellate Cells During Reversal of Liver FibrosisR01DK099205 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI BRENNER, DAVID A., KISSELEVA, TATIANA · 2014 to 2025
$4.8M
The Role of Portal Fibroblasts in Cholestatic Liver FibrosisR01DK101737 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI KISSELEVA, TATIANA · 2014 to 2025
$3.8M
Novel IL-23 inhibitor for the treatment of alcohol associated liver diseaseU01AA029019 · NIAAA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI KISSELEVA, TATIANA, LOOMBA, ROHIT · 2020 to 2024
$3.7M
The role of IL-17 signaling in alcohol-induced HCCR01AA028550 · NIAAA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI BRENNER, DAVID A., KISSELEVA, TATIANA · 2021 to 2025
$2.3M
Mechanisms by which hepatocyte extracellular miRNAs mediate peripheral insulin sensitivityR01DK125560 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI YING, WEI · 2021 to 2025
$2.0M
ANT2 in metaflammation and insulin resistanceR01DK124298 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI LEE, YUN SOK · 2021 to 2025
$1.9M
Effects of Fractalkine on Beta Cell FunctionR01DK101395 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI OLEFSKY, JERROLD MICHAEL · 2014 to 2017
$1.6M
Adipose tissue macrophages secrete exosome-miRs as paracrine/endocrine molecules to directly modulate insulin target cell function in response to obesityR00DK115998 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI YING, WEI · 2020 to 2022
$739k
Foundation for the National Institutes of Health (Foundation for the National Institutes of Health, Inc.) R00DK115998Foundation for the National Institutes of Health (Foundation for the National Institutes of Health, Inc.) R01DK125560Foundation for the National Institutes of Health (Foundation for the National Institutes of Health, Inc.) R21HD107516Larry L. Hillblom Foundation (Larry L. Hillblom Foundation, Inc.) 2023-D-011-FELLarry L. Hillblom Foundation (Larry L. Hillblom Foundation, Inc.) 2023-D-012-FELNIAAA NIH HHS P50 AA011999NIAAA NIH HHS R01 AA028550NIAAA NIH HHS U01 AA029019NICHD NIH HHS R21 HD107516NIDDK NIH HHS K99 DK115998NIDDK NIH HHS P30 DK063491NIDDK NIH HHS P30 DK120515NIDDK NIH HHS R00 DK115998NIDDK NIH HHS R01 DK091183NIDDK NIH HHS R01 DK099205NIDDK NIH HHS R01 DK101395NIDDK NIH HHS R01 DK101737NIDDK NIH HHS R01 DK124298NIDDK NIH HHS R01 DK125560Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (Swiss National Science Foundation) P2BSP3_200177UC | University of California, Los Angeles (UCLA) UCLA LIFT-UPU.S. Department of Health & Human Services | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (National Institute of Diabetes & Digestive & Kidney Diseases) DK124298U.S. Department of Health & Human Services | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (National Institute of Diabetes & Digestive & Kidney Diseases) P30DK063491U.S. Department of Health & Human Services | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (National Institute of Diabetes & Digestive & Kidney Diseases) R01DK101395
6 · The paper itself

Abstract

The obesity epidemic continues to worsen worldwide, driving metabolic and chronic inflammatory diseases. Thiazolidinediones, such as rosiglitazone (Rosi), are PPARγ agonists that promote 'M2-like' adipose tissue macrophage (ATM) polarization and cause insulin sensitization. As ATM-derived small extracellular vesicles (ATM-sEVs) from lean mice are known to increase insulin sensitivity, we assessed the metabolic effects of ATM-sEVs from Rosi-treated obese male mice (Rosi-ATM-sEVs). Here we show that Rosi leads to improved glucose and insulin tolerance, transcriptional repolarization of ATMs and increased sEV secretion. Administration of Rosi-ATM-sEVs rescues obesity-induced glucose intolerance and insulin sensitivity in vivo without the known thiazolidinedione-induced adverse effects of weight gain or haemodilution. Rosi-ATM-sEVs directly increase insulin sensitivity in adipocytes, myotubes and primary mouse and human hepatocytes. Additionally, we demonstrate that the miRNAs within Rosi-ATM-sEVs, primarily miR-690, are responsible for these beneficial metabolic effects. Thus, using ATM-sEVs with specific miRNAs may provide a therapeutic path to induce insulin sensitization.

Indexed as

Adipose TissueExtracellular VesiclesInsulin ResistanceMacrophagesRosiglitazoneAdipocytesAnimalsHumansInsulinMaleMiceMice, Inbred C57BLMicroRNAsObesityInsulinMicroRNAsRosiglitazone

Identifiers

PMID38605183
PMCPMC11430498
OpenAlexW4394718205

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.